Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin a receptor antagonist fluid retention

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 2, 2013, Pages 182-189

  Stuart, Deborah ^a   Chapman, Mark ^a   Rees, Sara ^a   Woodward, Stephanie ^a   Kohan, Donald E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ATRASENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WATER; CELL SPECIFICITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; EXTRACELLULAR SPACE; FLUID RETENTION; GENE TARGETING; HEART MUSCLE; HEMATOCRIT; HEMODILUTION; HIGH SODIUM INTAKE; IMPEDANCE PLETHYSMOGRAPH; MOUSE; NEPHRON; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE; SYSTOLIC BLOOD PRESSURE; VASODILATATION; WEIGHT GAIN;

ANIMALS; BODY FLUIDS; EDEMA; KIDNEY TUBULES, COLLECTING; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; NEPHRONS; ORGAN SPECIFICITY; PHENYLPROPIONATES; PYRIDAZINES; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; SODIUM CHLORIDE, DIETARY; SPECIES SPECIFICITY;

EID: 84880402164     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.205286     Document Type: Article

References (20)

1. Barton M and Kohan DE (2011) Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol 172:255-260.
2. Barton M and Yanagisawa M (2008) Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 86:485-498.
3. Battistini B, Berthiaume N, Kelland NF, Webb DJ, and Kohan DE (2006) Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med (Maywood) 231:653-695.
4. Boesen EI and Pollock DM (2010) Cooperative role of ETA and ETB receptors in mediating the diuretic response to intramedullary hyperosmotic NaCl infusion. Am J Physiol Renal Physiol 299:F1424-F1432.
5. Chapman ME, Hu L, Plato CF, and Kohan DE (2010) Bioimpedance spectroscopy for the estimation of body fluid volumes in mice. Am J Physiol Renal Physiol 299: F280-F283.
6. De Mey JG, Compeer MG, Lemkens P, and Meens MJPMT (2011) ETA-receptor antagonists or allosteric modulators? Trends Pharmacol Sci 32:345-351.
7. Evans NJ and Walker JW (2008) Sustained Ca21 signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger. Can J Physiol Pharmacol 86:526-535.
8. Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, and Kohan DE (2006) Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291:F1274-F1280.
9. Ge Y, Bagnall A, Stricklett PK, Webb D, Kotelevtsev Y, and Kohan DE (2008) Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol Renal Physiol 295:F1635-F1640.
10. Ge Y, Stricklett PK, Hughes AK, Yanagisawa M, and Kohan DE (2005) Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol Renal Physiol 289:F692-F698.
11. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, and Dawson NA (2009) Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebocontrolled, randomised, phase 2 trial. Eur Urol 55:1112-1123.
12. Kedzierski RM, Grayburn PA, Kisanuki YY, Williams CS, Hammer RE, Richardson JA, Schneider MD, and Yanagisawa M (2003) Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol. Mol Cell Biol 23:8226-8232.
13. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, and Barton M(2012) Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci 91:528-539.
14. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, and Andress DL (2011a) Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22:763-772.
15. Kohan DE, Rossi NF, Inscho EW, and Pollock DM (2011b) Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91:1-77.
16. Lynch IJ, Welch AK, Kohan DE, Cain BD, and Wingo CS (2013) Endothelin-1 inhibits sodium reabsorption by ETA and ETB receptors in the mouse cortical collecting duct. Am J Physiol Renal Physiol DOI: 10.1152/ajprenal.00613.2012.
17. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G, and ASCEND Study Group (2010) Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21:527-535.
18. Nakano D and Pollock DM (2009) Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension 53:324-330.
19. Shohet RV, Kisanuki YY, Zhao XS, Siddiquee Z, Franco F, and Yanagisawa M (2004) Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc Natl Acad Sci USA 101:2088-2093.
20. Stuart D, Rees S, Woodward SK, Koesters R, Strait KA, and Kohan DE (2012) Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion. BMC Nephrol 13:166.